Skip to main content
Top
Published in: Supportive Care in Cancer 10/2008

01-10-2008 | Short Communication

Evaluation of xerostomia in hematopoietic cell transplantation by a simple capacitance method device

Authors: Yuko Sugiura, Yoshihiko Soga, Sachiko Nishide, Kotoe Kono, Kanayo Takahashi, Nobuharu Fujii, Fumihiko Ishimaru, Mitsune Tanimoto, Fusanori Nishimura, Shogo Takashiba

Published in: Supportive Care in Cancer | Issue 10/2008

Login to get access

Abstract

Goals

Hematopoietic cell transplantation (HCT) may lead to the development of xerostomia. However, there have been few reports of xerostomia in HCT patients based on objective data. We investigated moisture in the oral mucosa in patients undergoing HCT by the capacitance method using a convenient device, Moisture Checker for Mucus® (MCM; Life Co., Ltd., Saitama, Japan).

Subjects and methods

Thirty-six patients undergoing HCT at Okayama University Hospital of Medicine and Dentistry (Male = 22, Female = 14; age = 41.6 ± 16.2 years old) were enrolled in this study. Moisture in the oral mucosa was measured by MCM in accordance with the manufacturer’s instructions. The results were obtained as MCM values (%), which are the weight percentage of water content in the oral mucosal epithelium. As controls, moisture of the oral mucosa was also examined in healthy volunteers (Male = 27, Female = 35; age = 43.0 ± 14.6 years old).

Main results

Throughout the examination period, MCM values were significantly lower in patients who underwent HCT than in controls. The degree of mucosal moisture in HCT patients showed wide interindividual differences.

Conclusion

The degree of mucosal moisture in HCT patients was low and showed wide interindividual differences. Evaluation of xerostomia using such a device may contribute to appropriate oral care with saliva substitute.
Literature
1.
go back to reference Amerongen AV, Veerman EC (2003) Current therapies for xerostomia and salivary gland hypofunction associated with cancer therapies. Support Care Cancer 11:226–231, Medline Amerongen AV, Veerman EC (2003) Current therapies for xerostomia and salivary gland hypofunction associated with cancer therapies. Support Care Cancer 11:226–231, Medline
2.
go back to reference Brandtzaeg P (1989) Salivary immunoglobulins. In: Tenovuo J (ed) Human saliva: clinical chemistry and microbiology, vol. II. CRC, Boca Raton, pp 1–54 Brandtzaeg P (1989) Salivary immunoglobulins. In: Tenovuo J (ed) Human saliva: clinical chemistry and microbiology, vol. II. CRC, Boca Raton, pp 1–54
3.
go back to reference Jensen SB, Pedersen AM, Reibel J, Nauntofte B (2003) Xerostomia and hypofunction of the salivary glands in cancer therapy. Support Care Cancer 11:207–225, MedlinePubMed Jensen SB, Pedersen AM, Reibel J, Nauntofte B (2003) Xerostomia and hypofunction of the salivary glands in cancer therapy. Support Care Cancer 11:207–225, MedlinePubMed
4.
go back to reference Longman LP, McCracken CF, Higham SM, Field EA (2000) The clinical assessment of oral dryness is a significant predictor of salivary gland hypofunction. Oral Dis 6:366–370, MedlinePubMed Longman LP, McCracken CF, Higham SM, Field EA (2000) The clinical assessment of oral dryness is a significant predictor of salivary gland hypofunction. Oral Dis 6:366–370, MedlinePubMed
5.
go back to reference Shahdad SA, Taylor C, Barclay SC, Steen IN, Preshaw PM (2005) A double-blind, crossover study of Biotene Oralbalance and BioXtra systems as salivary substitutes in patients with post-radiotherapy xerostomia. Eur J Cancer Care (Engl) 14:319–326, Medline. DOI 10.1111/j.1365-2354.2005.00587.x CrossRef Shahdad SA, Taylor C, Barclay SC, Steen IN, Preshaw PM (2005) A double-blind, crossover study of Biotene Oralbalance and BioXtra systems as salivary substitutes in patients with post-radiotherapy xerostomia. Eur J Cancer Care (Engl) 14:319–326, Medline. DOI 10.​1111/​j.​1365-2354.​2005.​00587.​x CrossRef
6.
go back to reference Sugiura Y, Soga Y, Tanimoto I, Kokeguchi S, Nishide S, Kono K, Takahashi K, Fujii N, Ishimaru F, Tanimoto M, Yamabe K, Tsutani S, Nishimura F, Takashiba S (2008) Antimicrobial effects of the saliva substitute, Oralbalance®, against microorganisms from oral mucosa in the hematopoietic cell transplantation period. Support Care Cancer 16:421–424, Medline. DOI 10.1007/s00520-007-0391-z PubMedCrossRef Sugiura Y, Soga Y, Tanimoto I, Kokeguchi S, Nishide S, Kono K, Takahashi K, Fujii N, Ishimaru F, Tanimoto M, Yamabe K, Tsutani S, Nishimura F, Takashiba S (2008) Antimicrobial effects of the saliva substitute, Oralbalance®, against microorganisms from oral mucosa in the hematopoietic cell transplantation period. Support Care Cancer 16:421–424, Medline. DOI 10.​1007/​s00520-007-0391-z PubMedCrossRef
9.
go back to reference Warde P, Kroll B, O'Sullivan B, Aslanidis J, Tew-George E, Waldron J, Maxymiw W, Liu FF, Payne D, Cummings B (2000) A phase II study of Biotene in the treatment of postradiation xerostomia in patients with head and neck cancer. Support Care Cancer 8:203–208, Medline. DOI 10.1007/s005200050286 PubMedCrossRef Warde P, Kroll B, O'Sullivan B, Aslanidis J, Tew-George E, Waldron J, Maxymiw W, Liu FF, Payne D, Cummings B (2000) A phase II study of Biotene in the treatment of postradiation xerostomia in patients with head and neck cancer. Support Care Cancer 8:203–208, Medline. DOI 10.​1007/​s005200050286 PubMedCrossRef
Metadata
Title
Evaluation of xerostomia in hematopoietic cell transplantation by a simple capacitance method device
Authors
Yuko Sugiura
Yoshihiko Soga
Sachiko Nishide
Kotoe Kono
Kanayo Takahashi
Nobuharu Fujii
Fumihiko Ishimaru
Mitsune Tanimoto
Fusanori Nishimura
Shogo Takashiba
Publication date
01-10-2008
Publisher
Springer-Verlag
Published in
Supportive Care in Cancer / Issue 10/2008
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-008-0470-9

Other articles of this Issue 10/2008

Supportive Care in Cancer 10/2008 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine